Salut Sant Joan De Reus — Clinical Trial Site

76 Registered trials

35 Currently recruiting

Organisation

Salut Sant Joan De Reus

Location

Reus, Spain

Identifier

ORG-100043349

Address

Avinguda Del Doctor Josep Laporte 2, 43204, Spain

Departments

-
#3448: Medicina Interna
#4204:Servicio Medicina Interna
3113: medicina interna
3311: Oncology
4204: Unitat de Medicina Vascular i Metabolisme
7004:Oncología
Cardiology
Intensive care medicine
Lipidology
Medical oncologist
Medical Oncology
Medicina Interna
Medicina vascular y metabolismo
Medicine
N/A
Oncolgy
Oncologia
Oncología Radioterápica
Oncology
Oncology Department
Oncology Service
Planta baja. Unidad investigación- AULA 6
Radiotherapy oncology service
Servicio de Medicina Vascular y Metabolismo.
Servicio de Medicina Interna
Servicio de Oncología Médica
Servicio de Oncologia Medica y Radioterapia Àrea d´Oncologia / Unitat Recerca Clínica (URCO)
Servicio Ongología
Vascular and Metabolism Unit

Clinical trials at this site (76)

Search interface

A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR… Recruiting

2023-510109-16-00 Acute Respiratory Distress Syndrome (ARDS) Due to Pneum 4 2025-01-06
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 4 2024-11-04
Phase II Study to Assess the Efficacy of Niraparib Rechallenge after Surgery in Ovarian Cancer Patients with Oligometastatic Progression (Th… Recruiting

2023-508258-24-00 Ovarian cancer (OC) with oligometastatic progression (O 4 2024-09-12
N-PLUS Recruiting

2022-502559-69-01 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 201 4 2024-07-04
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting

2023-504807-94-00 Breast Cancer; Advanced solid tumors including but not 7 2023-12-26
Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan. Recruiting

2023-505385-28-00 male or pre/post-menopausal women age ≥ 18 years with l 4 2023-10-19
Clinical trial of androgen deprivation therapy combined with salvage radiotherapy when treating prostate cancer that has suffered recurrence… Recruiting

2024-517666-41-00 Prostate Cancer 5 2023-03-13
Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Resectable, Early-stage (II to IIIB) Non-small Cell Lun 4 2022-06-10
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Study to Find Out How Safe and Effective AZD0780 Is for Adults with High 'Bad' Cholesterol from an Inherited Condition Ended

2025-520520-17-00 Heterozygous familial hypercholesterolaemia 5 2025-09-05
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended

2023-504922-20-00 Hypercholesterolemia 5 2024-08-23
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin… Ended

2024-518486-10-00 Non-Muscle Invasive Bladder Cancer 4 2023-02-23
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic … Ended

2023-509825-38-00 Metastatic Non–Small Cell Lung Cancer 5 2022-12-01
Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended

2023-503403-28-00 treatment naïve patients with HR+/HER2-negative high-ri 4 2022-11-25